Angiotech Pharmaceuticals, Inc.
Deal signed to extend paclitaxel technology into coronary bypass surgery
Published in Lab Law Weekly, April 22nd, 2005
The exclusive license agreement provides CABG Medical (CABG) with access to Angiotech's pioneering technology to treat restenosis and proliferative disease through the local delivery of the drug paclitaxel, and to Angiotech's extensive intellectual property portfolio related to this technology. CABG Medical will employ Angiotech's technology in the field of coronary artery bypass grafts.
In connection with the license agreement, Angiotech will receive a warrant to purchase 1,262,823 shares of CABG Medical's common stock, exercisable at $0.01 per...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
Source: Lab Law Weekly (2005-04-22)
More Articles from Lab Law Weekly
- Alizyme plc
Patent, IP rights to colonic drug delivery system acquired - Animas Corporation
Cygnus asset purchase consummated - Crucell, NV
Company secures patent license from NIH to commercialize Ebola vaccines - EDC Biosystems, Inc.
Patent awarded for acoustic method for pico to nano volume fluid transfer - Ethics
U.S. attempting to flout ethical practice for patient trials abroad - Imperial College London
British hospitals need clinical ethicists - More from this issue of Lab Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
